H.C. Wainwright Reiterates Buy Rating on Edgewise Therapeutics (EWTX)

October 14, 2026 7:16 AM EDT Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $57.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login